Search Results - "Tiedje, V."

Perspectives for immunotherapy in endocrine cancer by Latteyer, S, Tiedje, V, Schilling, B, Führer, D

“…The fight against cancer has seen major breakthroughs in recent years. More than a decade ago, tyrosine kinase inhibitors targeting constitutively activated…”
Get full text

The role of fibrinogen plasma levels, the -455G>A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis by Tiedje, V, Dunkler, D, Ay, C, Horvath, B, Quehenberger, P, Pabinger, M, Zielinski, C, Pabinger, I, Mannhalter, C

“…Venous thromboembolism (VTE) is a life-threatening complication in cancer patients. Identification of risk factors has been in focus in the past years…”
Get more information

Diabetes insipidus as a rare cause of acute cognitive impairment in multiple sclerosis by Tiedje, V, Schlamann, M, Führer, D, Moeller, LC

“…Multiple sclerosis (MS) is a complex neurodegenerative disease presenting with a diversity of clinical symptoms including palsy and cognitive impairment. We…”
Get full text

Differentiated thyroid cancer by Tiedje, V, Schmid, K W, Weber, F, Bockisch, A, Führer, D

“…Thyroid carcinoma is a rare and heterogeneous disease. Initial therapy and follow-up has to be adjusted to the individual risk for an excellent vs. poor…”
Get full text

Medullary thyroid carcinoma by Tiedje, V, Ting, S, Dralle, H, Schmid, K W, Führer, D

“…Medullary thyroid carcinoma (MTC) is a very rare malignancy, which arises from parafollicular C cells and accounts for 3-5% of all thyroid cancers. MTC…”
Get full text

Differenzierte Schilddrüsenkarzinome by Tiedje, V., Schmid, K.W., Weber, F., Bockisch, A., Führer, D.

“…Zusammenfassung Schilddrüsenkarzinome sind selten und klinisch sehr heterogen. Therapie und Nachsorge müssen auf das individuelle Risiko eines günstigen oder…”
Get full text

Das medulläre Schilddrüsenkarzinom by Tiedje, V., Ting, S., Dralle, H., Schmid, K.W., Führer, D.

“…Zusammenfassung Das medulläre Schilddrüsenkarzinom (MTC) entsteht aus den parafollikulären C-Zellen und macht etwa 3–5 % aller Schilddrüsenkarzinome aus. Als…”
Get full text

Management des fortgeschrittenen medullären Schilddrüsenkarzinoms: Therapie mit Tyrosinkinaseinhibitoren by Raue, F., Fassnacht, M., Führer, D., Frank-Raue, K., Luster, M., Kreissl, M.C., Müller, S., Musholt, T., Rüssel, J., Schott, M., Spitzweg, C., Tiedje, V.

“…Zusammenfassung Hintergrund Das medulläre Schilddrüsenkarzinom (MTC) ist ein langsam wachsender differenzierter neuroendokriner Tumor mit guter Prognose und…”
Get full text